Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026
Analysis of Long-Term Effects of Percutaneous Balloon Mitral Valvotomy (PBMV) in 90 Patients With Rheumatic Mitral Stenosis: A Retrospective Analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Jian, Liang Ning, Xiao Yongqi, Wu Xuenuo, Lu Dong, Li Chunping, Zeng Yizhou, Luo Xiyuan
Аннотация
BACKGROUND: Analysis of the long-term effects of percutaneous balloon mitral valvotomy (PBMV) intervention in patients with rheumatic mitral stenosis.
AIMS: To evaluate the long-term efficacy, safety, and hemodynamic outcomes of PBMV in patients with rheumatic heart disease and mitral stenosis through a 6-year retrospective clinical follow-up.
METHODS: Ninety patients with rheumatic mitral stenosis treated in our hospital from January 2012 to 2017 were selected retrospectively. The changes of cardiac function grade before and 1, 3, and 6 years after intervention, left atrial diameter (LADd), mitral valve area (MVA), transvalvular pressure difference (MVG), pulmonary artery systolic pressure (PAPs), left ventricular ejection fraction (LVEF), and restenosis 1, 3, and 6 years after intervention were observed.
RESULTS: Post-procedural NYHA functional class improved significantly compared with baseline (p < 0.05). NYHA class remained stable across 1-, 3-, and mid-term (6-year) follow-up visits, with no statistically significant differences between these time points. After 6 years of intervention, MVA and LVEF were still higher than those before intervention, while LADd, MVG, and PAPs were still lower than those before intervention (p < 0.05). There was no significant difference between the study cohort in terms of restenosis, complications, and cardiac adverse events at 1, 3, and 6 years after intervention (p > 0.05).
CONCLUSIONS: The long-term effect of PBMV is good in patients with rheumatic mitral stenosis.
AIMS: To evaluate the long-term efficacy, safety, and hemodynamic outcomes of PBMV in patients with rheumatic heart disease and mitral stenosis through a 6-year retrospective clinical follow-up.
METHODS: Ninety patients with rheumatic mitral stenosis treated in our hospital from January 2012 to 2017 were selected retrospectively. The changes of cardiac function grade before and 1, 3, and 6 years after intervention, left atrial diameter (LADd), mitral valve area (MVA), transvalvular pressure difference (MVG), pulmonary artery systolic pressure (PAPs), left ventricular ejection fraction (LVEF), and restenosis 1, 3, and 6 years after intervention were observed.
RESULTS: Post-procedural NYHA functional class improved significantly compared with baseline (p < 0.05). NYHA class remained stable across 1-, 3-, and mid-term (6-year) follow-up visits, with no statistically significant differences between these time points. After 6 years of intervention, MVA and LVEF were still higher than those before intervention, while LADd, MVG, and PAPs were still lower than those before intervention (p < 0.05). There was no significant difference between the study cohort in terms of restenosis, complications, and cardiac adverse events at 1, 3, and 6 years after intervention (p > 0.05).
CONCLUSIONS: The long-term effect of PBMV is good in patients with rheumatic mitral stenosis.